Overview

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers

Status:
Completed

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of a single subcutaneous dose of UB-621 in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

United BioPharma

Collaborator:

Taipei Veterans General Hospital, Taiwan